| albiglutide vs liraglutide | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | severe hypoglycemia | no data | | all hypoglycemia | no data | | diarrhoea | no data | | vomiting | no data | | A CHANGER | no data | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| albiglutide vs placebo | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | all hypoglycemia | no data | | severe hypoglycemia | no data | | treatment-emergent adverse events (TEAEs) | 2.25 [0.24 20.98] | p=1.00 | 0 | 40 | 1 | Seino, | | serious adverse events | no data | | severe adverse events | no data | | A CHANGER | 1.75 [0.08 37.72] | p=1.00 | 0 | 40 | 1 | Seino, | | vomiting | 1.75 [0.08 37.72] | p=1.00 | 0 | 40 | 1 | Seino, | | diarrhoea | 0.75 [0.03 20.31] | p=1.00 | 0 | 40 | 1 | Seino, | | All cause death | no data | | cardiovascular events | no data |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| albiglutide biweekly vs placebo (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | all hypoglycemia | no data | | severe hypoglycemia | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | A CHANGER | no data | | vomiting | no data | | diarrhoea | no data | | All cause death | no data | | cardiovascular events | 4.69 [0.18 118.77] | p=1.00 | 0 | 82 | 1 | Rosenstock (30 mg every two weeks), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
| albiglutide weekly vs placebo (add on MET) | No demonstrated result | | Endpoint | TE [95% CI] | p val | I2 | n | k | trials |
|---|
| Cardiovascular death | no data | | all hypoglycemia | no data | | severe hypoglycemia | no data | | treatment-emergent adverse events (TEAEs) | no data | | serious adverse events | no data | | severe adverse events | no data | | A CHANGER | no data | | vomiting | no data | | diarrhoea | no data | | All cause death | no data | | cardiovascular events | 1.65 [0.03 85.07] | p=1.00 | 0 | 82 | 1 | Rosenstock (30 mg weekly), |
TE: treatment effect; CI: confidence interval; k: nulmber of trials; n: total number of patients |
